Kidney Cancer Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Targeted Therapy, Immunotherapy, Radiation Therapy, Neurosurgical Treatments (Cryoablation, Radiofrequency ablation), By Class of drugs (mTOR Inhibitors, Angiogenesis Inhibitors, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region Forecast 2020-2031

Kidney Cancer Treatment Market size was valued at US$ 6.7 billion in 2024 and is expected to reach US$ 10.7 billion by 2031, growing at a significant CAGR of 6.9% from 2025-2031. The market refers to the market for developing therapeutics and treatment options specifically targeted at kidney cancer, also known as renal cell carcinoma (RCC). Kidney cancer is a type of cancer that originates in the kidneys, which are responsible for filtering waste from the blood and producing urine. It is a kind of cancer that is rather prevalent, with regional variations in incidence rates. The market encompasses a broad variety of treatment modalities, including surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and combination therapies. These therapies aim to stop or at least limit the proliferation of cancer cells, stop the disease from spreading, and enhance the patient’s quality of life. The market is primarily driven by the increasing incidence and prevalence of kidney cancer worldwide.

According to the World Cancer Research Journal, kidney cancer causes 144,000 deaths and 338,000 new cases worldwide each year. Other factors that support the expansion of the market include improvements in diagnostic procedures like computed tomography (CT) scans and magnetic resonance imaging (MRI), the creation of novel and targeted therapies like tyrosine kinase inhibitors and immune checkpoint inhibitors, and increase in research and development activities. Moreover, development of immunotherapy in kidney cancer treatment, adoption of minimally invasive surgical techniques and biomarker-based diagnosis and treatment crate favourable environment for the growth of the market in the forecasting years.

However, expensive kidney cancer treatment, especially when considering the cost of surgeries, targeted therapies, immunotherapies, and follow-up care can limit the access to advanced treatment options for some patients in regions with limited healthcare resources impede the market. Various pharmaceutical companies are introducing innovative treatment options and advancements in medical technology to further contribute to market growth. For instance, in November 2021, Merck’s KEYTRUDA (pembrolizumab) got FDA approval as adjuvant therapy for patients with renal cell carcinoma (RCC) following surgery.

Key Developments

• In October 2021, Biocon announced the launch of Everolimus tablets, a generic version of Afinitor, in the US.
• In March 2021, the FDA approved AVEO Oncology’s FOTIVDA for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC).